# Epidemiology and Biomarker Study in Alzheimer's Disease

Clinical trial · Eli Lilly and Company

- Archive id: nct:NCT07142954
- Published: 2025-08-27
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT07142954
- Source URL: https://clinicaltrials.gov/study/NCT07142954
- Provenance: clinicaltrials

## Abstract

Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: ANCHOR-AD
- status: RECRUITING
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 3400
- sponsor: Eli Lilly and Company
- conditions: Alzheimer Disease
- interventions: OTHER: P-tau217 Test
- start date: 2025-08-25
- start date type: ACTUAL
- primary completion date: 2033-07-01
- has results: false
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [Alzheimer's, Parkinson's & Neurodegeneration](https://space-kitty.com/topics/neurodegeneration)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.